Overview

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

Status:
Terminated
Trial end date:
2018-07-10
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of single intra-operative treatment of Botulinum Neurotoxin Serotype E (EB-001) intramuscular (IM) injections into the Rectus Abdominus (RA) in participants undergoing abdominoplasty.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Bonti, Inc.
Treatments:
Botulinum Toxins